Our lead product is Tracleer®, a dual endothelin receptor antagonist. Tracleer® was the first oral treatment approved for pulmonary arterial hypertension (PAH), a rare, chronic, life-threatening disorder that severely compromises the functions of the lungs and heart. Today, Tracleer® has been approved for the treatment of PAH in over 60 countries, including the United States in November 2001, the European Union in May 2002 and Japan in April 2005. We currently market Tracleer® in all major markets worldwide including the United States, the European Union, Japan, Switzerland, Canada, Australia and China.

In addition to the indication in PAH, based on compelling clinical data, Tracleer® received approval from the European regulatory authorities in 2007 for the reduction in the number of new digital ulcers in patients suffering from systemic sclerosis and ongoing digital ulcer disease.